Plain-English translation of NCT05594706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 1 research guide →Researchers are studying a blood marker called anhydroglucitol (or 1,5-AG) that may help measure how many healthy, functioning insulin-producing cells remain in children with type 1 diabetes. The study will look at whether this blood marker reliably reflects the health of these cells over time, from the moment of diagnosis through the first year and beyond. If successful, this measurement could one day help doctors better understand how a child's diabetes is progressing and inform treatment decisions.
In type 1 diabetes, the immune system gradually destroys the pancreas cells that produce insulin. Currently, there is no simple, reliable way to measure how many healthy cells remain. This study exists to test whether anhydroglucitol could be that simple blood test — helping doctors track pancreas health without invasive procedures.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood draws at specific visits: at the time of your diabetes diagnosis, four months later, and one year after diagnosis (if newly diagnosed); or at one time point if you have had diabetes for several years. Each visit involves a blood test to measure the anhydroglucitol level. You must continue using your insulin pump and continuous glucose monitor as usual during the study, and keep records of your blood sugar readings. The entire study lasts about one year from your enrollment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Switzerland
Sponsor
University Hospital, Geneva
Collaborators
University of Geneva, Switzerland
Enrollment target
~60 participants
Started
January 2023
Primary completion
December 2026
Age range
2 Years – 18 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Philippe Klee
University Hospital, Geneva
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.